BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22522623)

  • 1. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
    Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
    Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
    Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
    Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
    Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
    Obuchi M; Fernandez M; Barber GN
    J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curative one-shot systemic virotherapy in murine myeloma.
    Naik S; Nace R; Federspiel MJ; Barber GN; Peng KW; Russell SJ
    Leukemia; 2012 Aug; 26(8):1870-8. PubMed ID: 22425894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.
    Yarde DN; Naik S; Nace RA; Peng KW; Federspiel MJ; Russell SJ
    Cancer Gene Ther; 2013 Nov; 20(11):616-21. PubMed ID: 24176894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
    Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
    Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
    Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
    Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review.
    Moglan AM; Albaradie OA; Alsayegh FF; Alharbi HM; Samman YM; Jalal MM; Saeedi NH; Mahmoud AB; Alkayyal AA
    Front Immunol; 2023; 14():1085940. PubMed ID: 37063914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
    Smith KER; Peng KW; Pulido JS; Weisbrod AJ; Strand CA; Allred JB; Newsom AN; Zhang L; Packiriswamy N; Kottke T; Tonne JM; Moore M; Montane HN; Kottschade LA; McWilliams RR; Dudek AZ; Yan Y; Dimou A; Markovic SN; Federspiel MJ; Vile RG; Dronca RS; Block MS
    Front Immunol; 2023; 14():1279387. PubMed ID: 38022659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.
    Goel A; Carlson SK; Classic KL; Greiner S; Naik S; Power AT; Bell JC; Russell SJ
    Blood; 2007 Oct; 110(7):2342-50. PubMed ID: 17515401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.
    Yarde DN; Nace RA; Russell SJ
    Exp Hematol; 2013 Dec; 41(12):1038-49. PubMed ID: 24067362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.